Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc. News
May 11, 2025 - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Reach Out
May 8, 2025 - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out
May 6, 2025 - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation
May 4, 2025 - accessnewswire.com
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Lifecore Biomedical, Inc. Quantitative Score

About Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
Lifecore Biomedical, Inc. Earnings & Revenue
Lifecore Biomedical, Inc. Financials
Table Compare
Compare LFCR metrics with: | |||
---|---|---|---|
Earnings & Growth | LFCR | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LFCR | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LFCR | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LFCR | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Lifecore Biomedical, Inc. Income
Lifecore Biomedical, Inc. Balance Sheet
Lifecore Biomedical, Inc. Cash Flow
Lifecore Biomedical, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Sell |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Lifecore Biomedical, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Lifecore Biomedical, Inc. Executives
Name | Role |
---|---|
Dr. Albert D. Bolles Ph.D. | President of Curation Foods, Inc. |
Mr. James G. Hall | Advisor |
Mr. Parker K. Javid | Vice President |
Mr. Paul Josephs | President, Chief Executive Officer & Director |
Mr. Aaron Perlitsh | Director of Internal Audit & Chief Compliance Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Dr. Albert D. Bolles Ph.D. | President of Curation Foods, Inc. | 1958 | 1.34M | |
Mr. James G. Hall | Advisor | Male | 1963 | 642.75K |
Mr. Parker K. Javid | Vice President | Male | 1969 | 321.91K |
Mr. Paul Josephs | President, Chief Executive Officer & Director | Male | 1966 | 135.56K |
Mr. Aaron Perlitsh | Director of Internal Audit & Chief Compliance Officer | Male | -- |
Lifecore Biomedical, Inc. Insider Trades
Date | 5 May |
Name | English Aron R. |
Role | 10 percent owner |
Transaction | Disposed |
Type | S-Sale |
Shares | 24543 |
Date | 6 May |
Name | English Aron R. |
Role | 10 percent owner |
Transaction | Disposed |
Type | S-Sale |
Shares | 701 |
Date | 7 May |
Name | English Aron R. |
Role | 10 percent owner |
Transaction | Disposed |
Type | S-Sale |
Shares | 15847 |
Date | 14 Apr |
Name | Salus Thomas D. |
Role | Chief Legal & Administration |
Transaction | Acquired |
Type | A-Award |
Shares | 45000 |
Date | 14 Apr |
Name | Salus Thomas D. |
Role | Chief Legal & Administration |
Transaction | Acquired |
Type | A-Award |
Shares | 170000 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
5 May | English Aron R. | 10 percent owner | Disposed | S-Sale | 24543 |
6 May | English Aron R. | 10 percent owner | Disposed | S-Sale | 701 |
7 May | English Aron R. | 10 percent owner | Disposed | S-Sale | 15847 |
14 Apr | Salus Thomas D. | Chief Legal & Administration | Acquired | A-Award | 45000 |
14 Apr | Salus Thomas D. | Chief Legal & Administration | Acquired | A-Award | 170000 |